Cargando…

Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors

BACKGROUND: The coronavirus disease-2019 (COVID-19) is a systemic disease with severe implications on the vascular and coagulation system. A procoagulant platelet phenotype has been reported at least in the acute disease phase. Soluble P-selectin (sP-sel) in the plasma is a surrogate biomarker of pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Rebecca, Rink, Gabi, Uzun, Günalp, Bakchoul, Tamam, Wuchter, Patrick, Klüter, Harald, Bugert, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252887/
https://www.ncbi.nlm.nih.gov/pubmed/35810548
http://dx.doi.org/10.1016/j.thromres.2022.06.014
_version_ 1784740373911830528
author Müller, Rebecca
Rink, Gabi
Uzun, Günalp
Bakchoul, Tamam
Wuchter, Patrick
Klüter, Harald
Bugert, Peter
author_facet Müller, Rebecca
Rink, Gabi
Uzun, Günalp
Bakchoul, Tamam
Wuchter, Patrick
Klüter, Harald
Bugert, Peter
author_sort Müller, Rebecca
collection PubMed
description BACKGROUND: The coronavirus disease-2019 (COVID-19) is a systemic disease with severe implications on the vascular and coagulation system. A procoagulant platelet phenotype has been reported at least in the acute disease phase. Soluble P-selectin (sP-sel) in the plasma is a surrogate biomarker of platelet activation. Increased plasma levels of sP-sel have been reported in hospitalized COVID-19 patients associated with disease severity. Here, we evaluated in a longitudinal study the sP-sel plasma concentration in blood donors who previously suffered from moderate COVID-19. METHODS: 154 COVID-19 convalescent and 111 non-infected control donors were recruited for plasma donation and for participation in the CORE research trial. First donation (T1) was performed 43–378 days after COVID-19 diagnosis. From most of the donors the second (T2) plasma donation including blood sampling was obtained after a time period of 21–74 days and the third (T3) donation after additional 22–78 days. Baseline characteristics including COVID-19 symptoms of the donors were recorded based on a questionnaire. Platelet function was measured at T1 by flow cytometry and light transmission aggregometry in a representative subgroup of 25 COVID-19 convalescent and 28 control donors. The sP-sel plasma concentration was determined in a total of 704 samples by using a commercial ELISA. RESULTS: In vitro platelet function was comparable in COVID-19 convalescent and control donors at T1. Plasma samples from COVID-19 convalescent donors revealed a significantly higher sP-sel level compared to controls at T1 (1.05 ± 0.42 ng/mL vs. 0.81 ± 0.30 ng/mL; p < 0.0001) and T2 (0.96 ± 0.39 ng/mL vs. 0.83 ± 0.38 ng/mL; p = 0.0098). At T3 the sP-sel plasma level was comparable in both study groups. Most of the COVID-19 convalescent donors showed a continuous decrease of sP-sel from T1 to T3. CONCLUSION: Increased sP-sel plasma concentration as a marker for platelet or endothelial activation could be demonstrated even weeks after moderate COVID-19, whereas, in vitro platelet function was comparable with non-infected controls. We conclude that COVID-19 and additional individual factors could lead to an increase of the sP-sel plasma level.
format Online
Article
Text
id pubmed-9252887
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-92528872022-07-05 Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors Müller, Rebecca Rink, Gabi Uzun, Günalp Bakchoul, Tamam Wuchter, Patrick Klüter, Harald Bugert, Peter Thromb Res Full Length Article BACKGROUND: The coronavirus disease-2019 (COVID-19) is a systemic disease with severe implications on the vascular and coagulation system. A procoagulant platelet phenotype has been reported at least in the acute disease phase. Soluble P-selectin (sP-sel) in the plasma is a surrogate biomarker of platelet activation. Increased plasma levels of sP-sel have been reported in hospitalized COVID-19 patients associated with disease severity. Here, we evaluated in a longitudinal study the sP-sel plasma concentration in blood donors who previously suffered from moderate COVID-19. METHODS: 154 COVID-19 convalescent and 111 non-infected control donors were recruited for plasma donation and for participation in the CORE research trial. First donation (T1) was performed 43–378 days after COVID-19 diagnosis. From most of the donors the second (T2) plasma donation including blood sampling was obtained after a time period of 21–74 days and the third (T3) donation after additional 22–78 days. Baseline characteristics including COVID-19 symptoms of the donors were recorded based on a questionnaire. Platelet function was measured at T1 by flow cytometry and light transmission aggregometry in a representative subgroup of 25 COVID-19 convalescent and 28 control donors. The sP-sel plasma concentration was determined in a total of 704 samples by using a commercial ELISA. RESULTS: In vitro platelet function was comparable in COVID-19 convalescent and control donors at T1. Plasma samples from COVID-19 convalescent donors revealed a significantly higher sP-sel level compared to controls at T1 (1.05 ± 0.42 ng/mL vs. 0.81 ± 0.30 ng/mL; p < 0.0001) and T2 (0.96 ± 0.39 ng/mL vs. 0.83 ± 0.38 ng/mL; p = 0.0098). At T3 the sP-sel plasma level was comparable in both study groups. Most of the COVID-19 convalescent donors showed a continuous decrease of sP-sel from T1 to T3. CONCLUSION: Increased sP-sel plasma concentration as a marker for platelet or endothelial activation could be demonstrated even weeks after moderate COVID-19, whereas, in vitro platelet function was comparable with non-infected controls. We conclude that COVID-19 and additional individual factors could lead to an increase of the sP-sel plasma level. Elsevier Ltd. 2022-08 2022-07-05 /pmc/articles/PMC9252887/ /pubmed/35810548 http://dx.doi.org/10.1016/j.thromres.2022.06.014 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Full Length Article
Müller, Rebecca
Rink, Gabi
Uzun, Günalp
Bakchoul, Tamam
Wuchter, Patrick
Klüter, Harald
Bugert, Peter
Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors
title Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors
title_full Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors
title_fullStr Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors
title_full_unstemmed Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors
title_short Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors
title_sort increased plasma level of soluble p-selectin in non-hospitalized covid-19 convalescent donors
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252887/
https://www.ncbi.nlm.nih.gov/pubmed/35810548
http://dx.doi.org/10.1016/j.thromres.2022.06.014
work_keys_str_mv AT mullerrebecca increasedplasmalevelofsolublepselectininnonhospitalizedcovid19convalescentdonors
AT rinkgabi increasedplasmalevelofsolublepselectininnonhospitalizedcovid19convalescentdonors
AT uzungunalp increasedplasmalevelofsolublepselectininnonhospitalizedcovid19convalescentdonors
AT bakchoultamam increasedplasmalevelofsolublepselectininnonhospitalizedcovid19convalescentdonors
AT wuchterpatrick increasedplasmalevelofsolublepselectininnonhospitalizedcovid19convalescentdonors
AT kluterharald increasedplasmalevelofsolublepselectininnonhospitalizedcovid19convalescentdonors
AT bugertpeter increasedplasmalevelofsolublepselectininnonhospitalizedcovid19convalescentdonors